The online version of this article (doi:10.1186/s12936-017-1759-2) contains supplementary material, which is available to authorized users.
Despite increased efforts to control and ultimately eradicate human malaria, Plasmodium ovale malaria is for the most part outside the focus of research or public health programmes. Importantly, the understanding of P. ovale—nowadays regarded as the two distinct species P. ovale wallikeri and P. ovale curtisi—largely stems from case reports and case series lacking study designs providing high quality evidence. Consecutively, there is a lack of systematic evaluation of the clinical presentation, appropriate treatment and relapse characteristics of P. ovale malaria. The aim of this systematic review is to provide a systematic appraisal of the current evidence for severe manifestations, relapse characteristics and treatment options for human P. ovale malaria.
This systematic review was performed according to the PRISMA guidelines and registered in the international prospective register for systematic reviews (PROSPERO 2016:CRD42016039214). P. ovale mono-infection was a strict inclusion criterion. Of 3454 articles identified by the literature search, 33 articles published between 1922 and 2015 met the inclusion criteria. These articles did not include randomized controlled trials. Five prospective uncontrolled clinical trials were performed on a total of 58 participants. P. ovale was sensitive to all tested drugs within the follow-up periods and on interpretable in vitro assays. Since its first description in 1922, only 18 relapsing cases of P. ovale with a total of 28 relapse events were identified in the scientific literature. There was however no molecular evidence for a causal relationship between dormant liver stages and subsequent relapses. A total of 22 severe cases of P. ovale malaria were published out of which five were fatal. Additionally, two cases of congenital P. ovale malaria were reported.
Current knowledge of P. ovale malaria is based on small trials with minor impact, case reports and clinical observations. This systematic review highlights that P. ovale is capable of causing severe disease, severe congenital malaria and may even lead to death. Evidence for relapses in patients with P. ovale malaria adds up to only a handful of cases. Nearly 100 years after P. ovale’s first description by Stephens the evidence for the clinical characteristics, relapse potential and optimal treatments for P. ovale malaria is still scarce.
Additional file 1. Alphabetic list of included articles with overall quality of reporting and risk of bias assessment. -, not determined; overall risk of bias was declared “high” for case reports and case series; for applicable trials, overall risk of bias results from the detailed risk of bias assessment outlined in the Additional file 2; detailed completeness of reporting assessment is displayed in the Additional file 3.
Additional file 2. Detailed risk of bias assessment of prospective uncontrolled clinical trials. Key: 3 or more bias high risk: over all high risk of bias; 3 or more bias medium risk, 2 or less bias high risk: over all medium risk of bias.
Additional file 3. Detailed completeness of reporting assessment with a focus on P. ovale relevant information. NA, not applicable; CD, cannot be determined; *, for hyper endemic areas adequate length of follow-up was 14 days, otherwise 28 days; ~, total parasitaemia of patients given, else well described; Key: one partial or CD, else yes and NA: good; one no and one partial or CD, else yes: medium; 2-3 times partial and CD, else yes: medium; more than 3 partial and CD: poor; more than 2 no: poor.
WHO. World malaria report 2015. Geneva: World Health Organization; 2015. http://www.who.int/malaria/media/world-malaria-report-2015/en/. Accessed 02 Aug 2016.
Stephens J. A new malaria parasite of man. Ann Trop Med Parasitol. 1922;16:383–6. CrossRef
Blair DM. Infections with Plasmodium ovale Stephens in Southern Rhodesia. Trans R Soc Trop Med Hyg. 1938;32(229–31):33–6.
Stephens J, Owen DU. Plasmodium ovale. Ann Trop Med Parasitol. 1927;21:293–302. CrossRef
Severe malaria. Trop Med Int Health. 2014;19:7–131.
Viswanathan M, Ansari MT, Berkman ND, Chang S, Hartling L, McPheeters M, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. In Methods guide for effectiveness and comparative effectiveness reviews. Rockville; 2008.
The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions Version 5.1.0. 2011. www.handbook.cochrane.org. Accessed 15 Aug 2016.
National Institutes of Health Quality Assessment Tool for Case Series Studies. https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/case_series. Accessed 11 Nov 2016.
Same-Ekobo A. Rapid resolution of Plasmodium ovale malaria using artesunate (arsumax ®). Med Trop (Mars). 1999;59:43–5.
Danis M, Legros F, Gay F, Brousse G, Bricaire F, Gentilini M. Imported malaria in France. Med Mal Infect. 1999;29:257S–73S. CrossRef
Danis M, Felix H, Brucker G, Druilhe P, Datry A, Richard-Lenoble D, et al. Mefloquine: comparative therapy of Plasmodium falciparum, Plasmodium vivax and Plasmodium ovale malaria. Med Trop (Mars). 1982;42:427–32.
Rojo-Marcos G, Cuadros-Gonzalez J, Mesa-Latorre JM, Culebras-Lopez AM, de Pablo-Sanchez R. Acute respiratory distress syndrome in a case of Plasmodium ovale malaria. Am J Trop Med Hyg. 2008;79:391–3. PubMed
Penazzato M, Rampon O, De Canale E, De Rossi A, Mazza A, D’Elia R, et al. Congenital Plasmodium ovale malaria in an infant born to HIV positive mother. J Pediatr Infect Dis. 2007;2:167–9.
Collins WE, Jeffery GM. A retrospective examination of sporozoite-induced and trophozoite-induced infections with Plasmodium ovale: development of parasitologic and clinical immunity during primary infection. Am J Trop Med Hyg. 2002;66:492–502. PubMed
Chin W, Coatney GR. Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale. Am J Trop Med Hyg. 1971;20:825–7. PubMed
Jeffery GM, Young MD, Wilcox A. The Donaldson strain of malaria. 1. History and characteristics of the infection in man. Am J Trop Med Hyg. 1954;3:628–37. PubMed
WHO: guidelines for the treatment of malaria. Geneva: World Health Organization. 2015. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1&ua=1. Accessed 02 Aug 2016.
Lahlou H, Benjelloun S, Khalloufi A, Moudden EL, Hachimi MA, Errami M, et al. An exceptional observation of acute respiratory distress associated with Plasmodium ovale infection. Clin Chem Lab Med. 2012;50:A141.
Duffy PE, Fried M. Malaria in the pregnant woman. Curr Top Microbiol Immunol. 2005;295:169–200. PubMed
Krotoski WA, Collins WE, Bray RS, Garnham PC, Cogswell FB, Gwadz RW, et al. Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg. 1982;31:1291–3. PubMed
Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CSN, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. 2015;12:e1001891. CrossRefPubMedPubMedCentral
Sinton JA. Studies of infections with Plasmodium ovale. V. The effects of multiple inoculations upon the degree and nature of the immunity developed. Trans R Soc Trop Med Hyg. 1940;33:585–95. CrossRef
Sinton JA, Hutton EL, Shute PG. Studies of infections with Plasmodium ovale. II. Acquired resistance to ovale infections. Trans R Soc Trop Med Hyg. 1939;33:47–68. CrossRef
Sinton JA, Bird W. Studies in malaria, with special reference to Treatment. IX. Plasmoquine in the treatment of malaria. Indian J Med Res. 1928;16:159–78.
Desjardins RE, Doberstyn EB, Wernsdorfer WH. Principles and practice of malariology. London: Churchill Livingstone Inc; 1988.
Starzengruber P, Fuehrer HP, Swoboda P, Khan WA, Yunus EB, Hossain SM, et al. The first case of Plasmodium ovale malaria from Bangladesh. BMJ Case Rep. 2010;2010:02865.
Fuehrer HP, Habler VE, Fally MA, Harl J, Starzengruber P, Swoboda P, et al. Plasmodium ovale in Bangladesh: genetic diversity and the first known evidence of the sympatric distribution of Plasmodium ovale curtisi and Plasmodium ovale wallikeri in southern Asia. Int J Parasitol. 2012;42:693–9. CrossRefPubMed
Lemmerer R, Unger M, Vossen M, Forstner C, Jalili A, Starzengruber P, et al. Case report: spontaneous rupture of spleen in patient with Plasmodium ovale malaria. Wien Klin Wochenschr. 2015.
Coton T, Debourdeau P, Schoenlaub P, Grassin F, Maslin J. Péricardite aigue associée à un accès palustre de reviviscence un Plasmodium ovale. Med Trop (Mars). 2011;71:79–80.
Rubinstein J, Fischer RA, Newman RD, Parise ME, Johnston SP, Young J. Late relapse of Plasmodium ovale as malaria-Philadelphia, Pennsylvania, November 2004. MMWR Morb Mortal Wkly Rep. 2005;54:1231–3.
Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, et al. Malaria surveillance-United States, 2001. Morb Mortal Wkly Rep Surveill Summ. 2003;52:1–14.
Patel MI. Spontaneous rupture of a malarial spleen. Med J Aust. 1993;159:836–7. PubMed
Monlun E, Christmann D, Kremer M, Rey D, Storck D. Myocardial involvement in malaria. Rev Med Interne. 1989;13:433–6.
Bock E. Epidemiological, clinical and parasitological features of malaria produced by Plasmodium ovale Stephens, 1922. Archiv für Schiffs-und Tropenhygiene. 1939;43:327–53.
- A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria
Hannah S. Fischer
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II